GLP-1 Receptor Agonists and Cardiovascular Events in Adults with Obesity and Autoimmune Disease: A Target Trial Emulation

Hao Dai, Yao An Lee, Austin Natalie, Whitney L. Jackson, Angela Pham, Jake Levine, Rotana M. Radwan, Jingchuan Guo, Jiang Bian, Amy SheermedRxiv 2025 · DOI

Abstract: Among adults with obesity and AID, GLP-1RA use was associated with reduced thromboembolic events, lower emergency department utilization, and decreased mortality. These findings suggest potential cardiovascular and survival benefits of GLP-1RAs in a high-risk, understudied population.

Introduction

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide and tirzepatide, have revolutionized the management of obesity and Type 2 diabetes. Clinical trials have consistently demonstrated their efficacy in reducing major adverse cardiovascular events (MACE). However, a significant clinical gap remains: patients with systemic autoimmune diseases (AID), such as rheumatoid arthritis or lupus, are frequently excluded from these landmark trials.

Patients with AID face a unique "double whammy." They suffer from chronic systemic inflammation, which, when compounded by obesity, drastically elevates the risk of myocardial infarction, stroke, and venous thromboembolism. This study addresses this evidence gap by investigating whether the cardioprotective and survival benefits of GLP-1RAs extend to this high-risk, vulnerable population.

Methodology: Target Trial Emulation

In the absence of dedicated randomized controlled trials (RCTs) for this demographic, the researchers employed a "target trial emulation" framework. This statistical approach applies the rigors of a controlled experiment to real-world electronic health record (EHR) data to minimize bias.

Data Source and Cohort Selection

The study utilized the OneFlorida+ network, a massive longitudinal database containing EHRs for over 21 million individuals across Florida, Georgia, and Alabama. The analysis spanned a decade, from January 2014 to January 2024.

To ensure a robust comparison, the researchers implemented several technical safeguards:

  • New-User Design: Only patients initiating GLP-1RA therapy for the first time were included, avoiding "prevalent user bias."
  • Propensity Score Matching: 13,204 GLP-1RA users were matched 1:1 with 13,204 non-users. Matching criteria included age, BMI, comorbidities, smoking status, and baseline medications to mimic the randomization process of an RCT.
  • Time-Dependent Alignment: The "index date" for treatment initiation was aligned within a one-week window for both groups to ensure comparisons occurred during similar clinical periods.

Key Findings

The study revealed that GLP-1RA use is associated with a profound reduction in mortality and specific cardiovascular complications among patients with obesity and AID.

Survival and Thromboembolic Outcomes

The most striking finding was a 44% reduction in all-cause mortality (Hazard Ratio [HR] 0.56; 95% CI, 0.47-0.66). Additionally, the drugs showed a significant protective effect against blood clots:

  • Pulmonary Embolism (PE): 31% reduction (HR 0.69).
  • Venous Thromboembolism (VTE): 17% reduction (HR 0.83).
  • Stroke/TIA: 13% reduction (HR 0.87).

Healthcare Utilization

Beyond clinical events, GLP-1RA users experienced a 21% reduction in Emergency Department (ED) visits (HR 0.79). While the rate of full hospitalizations did not change significantly, the drop in ED utilization suggests improved overall management of chronic health conditions.

Discussion: The Anti-Inflammatory Hypothesis

One of the most intriguing insights from this study is the disparity between different types of cardiovascular events. While GLP-1RAs significantly reduced thromboembolic events (clots), the associations for myocardial infarction (heart attack) and coronary revascularization were not statistically significant in this specific population.

This suggests that in patients with AID, the primary benefit of GLP-1RAs may be their direct modulation of the immune system and antithrombotic properties, rather than just the management of traditional plaque-based atherosclerosis. Because inflammation is the primary driver of vascular damage in AID, the direct anti-inflammatory effects of GLP-1RAs may be the "killer feature" that drives the observed 44% reduction in mortality.

Limitations and Future Directions

As an observational study using EHR data, several limitations exist:

  • Unmeasured Confounding: Factors such as socioeconomic status, specific AID disease activity scores, and precise dosages of immunosuppressants were not fully captured.
  • Weight Loss Dynamics: The study did not quantify the degree of weight loss, making it difficult to determine how much of the benefit stems from the drug’s direct biological action versus secondary effects of weight reduction.
  • Medication Switching: The analysis did not account for patients switching between different GLP-1RAs during the study period.

Future prospective clinical trials are essential to confirm these findings and to elucidate the exact molecular mechanisms by which GLP-1RAs mitigate systemic inflammation in autoimmune populations. Nevertheless, these results provide strong evidence that GLP-1RAs are a potent tool for improving survival in high-risk patients with obesity and AID.

Summary updated

Abstract

Among adults with obesity and AID, GLP-1RA use was associated with reduced thromboembolic events, lower emergency department utilization, and decreased mortality. These findings suggest potential cardiovascular and survival benefits of GLP-1RAs in a high-risk, understudied population.
BibTeX
@misc{dai2025glp,
  author = {Hao Dai and Yao An Lee and Austin Natalie and Whitney L. Jackson and Angela Pham and Jake Levine and Rotana M. Radwan and Jingchuan Guo and Jiang Bian and Amy Sheer},
  title = {{GLP-1 Receptor Agonists and Cardiovascular Events in Adults with Obesity and Autoimmune Disease: A Target Trial Emulation}},
  year = {2025},
  doi = {10.1101/2025.11.10.25339912},
  howpublished = {medRxiv},
}
Figure